随机临床试验：多物种益生菌与先天免疫功能，细菌移位和

StephenW

Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis

First published: 4 September 2016Full publication history

• DOI: 10.1111/apt.13788View/save citation
• Cited by: 0 articles
  

• 
• Funding Information
  

• The Handling Editor for this article was Professor Peter Hayes, and it was accepted for publication after full peer-review.
  

SummaryBackgroundProbiotics may correct intestinal dysbiosis and proinflammatory conditions in patients with liver cirrhosis.
AimTo test the effects of a multispecies probiotic on innate immune function, bacterial translocation and gut permeability.
MethodsIn a randomised, double blind, placebo-controlled study, stable cirrhotic out-patients either received a daily dose of a probiotic powder containing eight different bacterial strains (Ecologic Barrier, Winclove, Amsterdam, The Netherlands) (n = 44) or a placebo (n = 36) for 6 months and were followed up for another 6 months.
ResultsWe found a significant but subclinical increase in neutrophil resting burst (2.6–3.2%, P = 0.0134) and neopterin levels (7.7–8.4 nmol/L, P = 0.001) with probiotics but not with placebo. Probiotic supplementation did not have a significant influence on neutrophil phagocytosis, endotoxin load, gut permeability or inflammatory markers. Ten severe infections occurred in total; one during intervention in the placebo group, and five and four after the intervention has ended in the probiotic and placebo group, respectively. Liver function showed some improvement with probiotics but not with placebo.
ConclusionsProbiotic supplementation significantly increased serum neopterin levels and the production of reactive oxygen species by neutrophils. These findings might explain the beneficial effects of probiotics on immune function. Furthermore, probiotic supplementation may be a well-tolerated method to maintain or even improve liver function in stable cirrhosis. However, its influence on gut barrier function and bacterial translocation in cirrhotic patients is minimal.

StephenW

随机临床试验：多物种益生菌与先天免疫功能，细菌移位和肠道通透性安慰剂肝硬化患者的影响
作者

    首先公布：9月4日出版2016Full历史
    DOI：10.1111 / apt.13788View /保存引文
    0文章：由引

    文章的6的比分altmetric
    资金的信息

    这篇文章的编辑处理是彼得·海斯教授，它被接受后满同行评审的出版物。

概要
背景

益生菌可以纠正肠道微生态失调和肝硬化患者促炎症条件。
目标

为了测试对先天免疫功能，细菌易位和肠渗透性的多物种益生菌的效果。
方法

在一项随机，双盲，安慰剂对照的研究中，稳定肝硬化门诊病人任一接收到包含八个不同的细菌菌株（生态屏障，Winclove，阿姆斯特丹，荷兰）益生菌粉末的每日剂量（N = 44）或安慰剂（N = 36），6个月并再随访6个月。
结果

我们发现在嗜中性粒细胞休息突发与益生菌显著但亚临床增加（2.6-3.2％，P = 0.0134）和新蝶呤水平（7.7-8.4纳摩尔/ L，P = 0.001），但不与安慰剂。补充益生菌并没有对中性粒细胞吞噬，内毒素负荷，肠道通透性或炎症标记物的显著的影响。十大严重感染发生在总;一项所述的安慰剂组中的干预期间，五，四，干预之后益生菌和安慰剂组中分别结束了。肝功能表现出一定的改善与益生菌但不与安慰剂。
结论

益生菌补充剂显著增加的血清新蝶呤水平和嗜中性粒细胞的活性氧物种。这些发现或许可以解释免疫功能益生菌的有利影响。此外，补充益生菌可以是维持或甚至改善在稳定肝硬变肝功能的耐受性良好的方法。然而，它在肝硬化患者对肠道屏障功能，细菌易位的影响是最小的。

MP4

http://b2b.winclove.nl/Our-formulations/ecologic.html
http://b2b.winclove.nl/images/Ecologic_BARRIER.pdf
http://www.medimart.com.hk/index.php?route=product/product&product_id=720#.V9I5MXS3PqB